Healthcare [ 5/11 ] | Biotechnology [ 54/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 3, 23 | -0.68 Decreased by -21.43% | -0.62 Decreased by -15.61% |
| Feb 28, 23 | -0.66 Decreased by -22.22% | -0.70 Increased by +8.16% |
| Nov 2, 22 | -0.58 Decreased by -1.75% | -0.64 Increased by +14.65% |
| Aug 9, 22 | -0.52 Increased by +1.89% | -0.61 Increased by +24.19% |
| May 4, 22 | -0.56 Decreased by -124.00% | -0.58 Increased by +5.95% |
| Feb 23, 22 | -0.54 Decreased by -1.89% | -0.60 Increased by +16.67% |
| Nov 4, 21 | -0.57 Decreased by -9.62% | -0.56 Decreased by -3.19% |
| Aug 4, 21 | -0.53 Increased by 0.00% | -0.55 Increased by +6.61% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 52.00 K Decreased by -14.75% | -98.34 M Decreased by -23.37% | Decreased by -189.11 K% Decreased by -44.73% |
| Dec 31, 22 | 47.00 K Decreased by -7.84% | -93.32 M Decreased by -24.65% | Decreased by -198.55 K% Decreased by -35.25% |
| Sep 30, 22 | 49.00 K Increased by 0.00% | -82.15 M Decreased by -5.06% | Decreased by -167.64 K% Decreased by -5.06% |
| Jun 30, 22 | 86.00 K Increased by +95.45% | -74.47 M Decreased by -4.98% | Decreased by -86.60 K% Increased by +46.29% |
| Mar 31, 22 | 61.00 K Decreased by -99.84% | -79.71 M Decreased by -141.43% | Decreased by -130.67 K% Decreased by -151.66 K% |
| Dec 31, 21 | 51.00 K Increased by +N/A% | -74.87 M Decreased by -9.18% | Decreased by -146.80 K% Decreased by N/A% |
| Sep 30, 21 | 49.00 K Increased by +N/A% | -78.19 M Decreased by -18.11% | Decreased by -159.56 K% Decreased by N/A% |
| Jun 30, 21 | 44.00 K Increased by +N/A% | -70.94 M Decreased by -16.34% | Decreased by -161.22 K% Decreased by N/A% |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.